## Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

BIOCRYST PHA Form 4 May 06, 2014	ARMACEUT	FICALS I	NC						
FORM 4									PPROVAL
Check this box	UNITED	STATES		RITIES A shington			COMMISSION	N OMB Number: Expires:	3235-0287 January 31,
if no longer subject to Section 16. Form 4 or	STATEM	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							2005 average urs per 0.5
Form 5 obligations may continue. <i>See</i> Instruction 1(b).	Section 17(	a) of the l	Public U	tility Hol	ding Cor		nge Act of 1934, of 1935 or Sectio 940		
(Print or Type Respon	nses)								
1. Name and Addres Jensen Peder	ss of Reporting	Person <u>*</u>	Symbol			• Trading EUTICAL	5. Relationship o Issuer S (Che	of Reporting Pe eck all applicab	
(Last)	(First) (1	Middle)	3. Date o	f Earliest T	ransaction		X_ Director		% Owner her (specify
4505 EMPEROF 200	R BLVD., SI	JITE	(Month/I 05/02/2	Day/Year) 014			below)	below)	lier (opeen)
,	Filed(Month/Day/Year) Applicabl _X_Form					Applicable Line) _X_ Form filed by Form filed by	or Joint/Group Filing(Check e) by One Reporting Person by More than One Reporting		
,	(State)	(Zip)	Tab	la I Nan I	Doministino	Securities A	Person .cquired, Disposed	of on Donofici	ally Owned
1.Title of 2. Tra	ansaction Date hth/Day/Year)		ed Date, if	3. Transactio Code (Instr. 8)	4. Securit	ies (A) or of (D)	5. Amount of Securities Beneficially Owned	<ul><li>6. Ownership</li><li>Form: Direct</li><li>(D) or Indirect</li><li>(I)</li></ul>	7. Nature of Indirect Beneficial Ownership
				Code V	Amount	<ul><li>(A)</li><li>or</li><li>(D) Price</li></ul>	Following Reported Transaction(s) (Instr. 3 and 4)	(Instr. 4)	(Instr. 4)
Reminder: Report on	n a separate line	e for each cl	ass of secu	urities benef	•	•	•		
					inforn requii	nation cont red to respo ays a currer	pond to the colle ained in this form ond unless the for ntly valid OMB co	n are not rm	SEC 1474 (9-02)
	Tab					posed of, or convertible s	Beneficially Owned securities)	1	

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amoun
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transact	ionDerivative	Expiration Date	Underlying Securiti

## Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year)		(Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amou or Numl of Sh
Automatic Stock Option Grant (1)	\$ 8.47	05/02/2014		А	15,000	06/02/2014 <u>(2)</u>	05/02/2024	Common Stock	15,0

## **Reporting Owners**

Reporting Owner Name / Address	Relationships								
	Director	10% Owner	Officer	Other					
Jensen Peder 4505 EMPEROR BLVD. SUITE 200 DURHAM, NC 27703	Х								
Signatures									
/s/ Alane P. Barnes, by power of attorney	of								
**Signature of Reporting Person		Da							

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.
- (2) Vests 1/12 per month over twelve months beginning June 2, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.